Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial.

@article{Andersson2002RaloxifeneDN,
  title={Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial.},
  author={Bj{\"o}rn Andersson and Gudmundur Johannsson and Goran Holm and B. -{\AA} Bengtsson and Andreas I. Sashegyi and Imre J. Pavo and Timothy Mason and Pamela W. Anderson},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2002},
  volume={87 1},
  pages={122-8}
}
Little is known about the metabolic or cardiovascular effects of selective ER modulators (SERMs), such as raloxifene hydrochloride (RLX), in postmenopausal women with type 2 diabetes mellitus (DM). Therefore, the effect of RLX vs. placebo (PL) on glycemic control, insulin sensitivity, as well as effects on a number of hormone, lipid, coagulation, and safety factors were determined in 30 postmenopausal women with type 2 DM in a randomized, double blind, cross-over trial. All participants had a… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

Raloxifene modifies the insulin sensitivity and lipid profile of postmenopausal insulin resistant women.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology • 2013
View 2 Excerpts

Similar Papers

Loading similar papers…